Combination therapy clinical trial now recruiting patients with metastatic colorectal cancer


Colorectal cancer starts when cells in the colon or rectum begin to grow out of control. In advanced stages, this type of cancer does not respond well to immunotherapy. A new clinical trial tests an approach to treating colorectal cancer that has not responded to other therapies. Pexa-Vec is derived from the vaccinia virus, which has been shown to kill cancer cells. The Pexa-Vec used in this study has been designed to express GM-CSF as well, which may boost the immune system’s ability to attack tumor cells. Patients in the study will also receive tremelimumab and durvalumab, both of which block proteins that keep T cells from attacking tumor cells. T cells are a major factor in the body’s immune response. The study, led by Tim Greten, M.D., of the Thoracic and Gastrointestinal Oncology Branch aims to find out if this drug combination is safe, and if patients with refractory colorectal cancer have a positive response to treatment.

For more information about this trial, visit: https://ccr.cancer.gov/thoracic-and-gastrointestinal-oncology-branch/tim-f-greten

Search all CCR clinical trials, and subscribe to have the latest CCR clinical trials sent to your inbox.

Summary Posted: 09/2017